Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms

Abstract

Figures

Full text

Correction to: Blood Cancer Journal (2022) 12:37 10.1038/s41408-022-00628-2, published online 07 March 2022

Following the publication of this article, errors were noted in Figures 4G and 7A. Upon reviewing the original data, it was realized that H&E staining for the Fedra 30mg/kg in the Ba/F3-EPOR-JAK2^V617F^ malignancy mouse model (Fig. 4G) was inaccurately analyzed as those from the JAK2^V617F^-induced MPN mouse model (Fig. 3D). This resulted in reuse of data from the Fedra 30mg/kg group. The corrected figure is presented below.

In Figure 7A, the image labeled 0.05 μM for Patient 2# is incorrect. Upon comparing with the original data, an error was determined due to the fact that 2 images were captured for each concentration. The data marked as 0 μM was mistakenly used in place of the 0.05 μM data during organization. The accurate data for Patient 2# is presented below.

The authors confirm these changes have no impact on the conclusions of the study and apologize for any inconvenience caused by these errors.

Fig. 4 Efficacy of FM against Ba/F3-EPOR-JAK2^V617F^ malignancy mouse model. BALB/c-nude mice were intravenously injected with 1.0 × 10^6^ Ba/F3-EPOR-JAK2^V617F^ –GFP cells and treated with vehicle, FM 15, 30, and 45 mg/kg and fedratinib 30 mg/kg bid. p.o. after 24 h, and the mice were sacrificed after 16 days of treatment. A Kaplan-Meier analysis of survival in Ba/F3-EPOR-JAK2^V617F^ mice in vehicle and FM or fedratinib treatment groups (n = 7). B White blood cell counts in PB were analyzed (n = 5). C Circulating IL-6 and TNF-α levels were analyzed in blood serum by ELISA (n = 7). D Fluorescence-activated cell sorting (FACS) analysis of the percentage of GFP^+^ cells in the PB at the end of the treatment (n = 7). E The size and weight of the spleen were acquired, and the spleen suppression rate was evaluated (n = 7). F Liver weights were analyzed (n = 7). G Splenic architecture and the extent of myelo-erythroid infiltration of the spleen and liver were observed in vehicle-treated animals compared to FM-treated animals. P-STAT3 and p-STAT5 levels were analyzed by IHC in the spleen. White pulp (yellow arrow), red pulp (green arrow), and tumor cell infiltration (green arrow) were marked. Images were obtained at ×100 and ×200 magnification. The histogram on the right panel is the quantitative statistics of IHC staining results performed by Image-Pro Plus. Data are represented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle, t-test.

Fig. 7 Effects of FM on erythroid colony formation and JAK2/STAT signaling in MPN patient samples with activating JAK2^V617F^ mutation. A Mononuclear cells were isolated from the PB or BM of patients with MPNs (Patient Number: 1#, 2#, and 3#), and incubated with FM in methylcellulose-based media. Hematopoietic colony-forming capacity was calculated by the total number of BFU-E, CFU-M, and CFU-GEMM on day 14. B MPN patient cells (Patient Number: 2#, 4#, and 5#) were incubated with various concentrations of FM for 4 h, and the phosphorylation of STAT3 and STAT5 were analyzed via western blot analysis. Data are represented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle, t-test.